Study Information

How Long is the Study?

Double-Blind Period

- The total study duration is up to 26 weeks or approximately 6 months including screening, baseline, treatment, and follow-up
  - Up to 4 weeks of screening
  - 8 weeks of baseline assessment
- You will receive a total of 8 weeks of daily treatment (XEN1101 or placebo) during the double-blind period of the study
- There will be a 6 week follow-up period after treatment is completed
- You will need to attend 8-10 clinic visits
Open-Label Extension Period

- If you are eligible to continue into the open-label extension period of the study, you could receive up to 52 weeks or approximately 1 year of daily treatment
- Everyone will receive active study drug (XEN1101) during the open-label extension period of the study

52 weeks

- There will be a 6 week follow-up period after treatment is completed
- You will need to attend 7 clinic visits